Adeno-Associated Virus Delivery of Anti-HIV Monoclonal Antibodies Can Drive Long-Term Virologic Suppression

José M. Martinez-Navio, Sebastian P. Fuchs, Shara N. Pantry, William A. Lauer, Natasha N. Duggan, Brandon F. Keele, Eva G. Rakasz, Guangping Gao, Jeffrey D. Lifson, Ronald Charles Desrosiers

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Although anti-retroviral drug therapy can suppress HIV viral replication, it is not a cure. Martinez-Navio et al. report the functional cure of the “Miami monkey,” in which long-term SHIV suppression was achieved after a single administration of adeno-associated viruses (AAVs) encoding broadly neutralizing antibodies. They also report that host-generated anti-antibodies can hamper the applicability of this approach.

Original languageEnglish (US)
Pages (from-to)567-575.e5
JournalImmunity
Volume50
Issue number3
DOIs
StatePublished - Mar 19 2019

Fingerprint

Dependovirus
HIV Antibodies
Neutralizing Antibodies
Haplorhini
Anti-Idiotypic Antibodies
Monoclonal Antibodies
HIV
Drug Therapy

Keywords

  • AAV vector
  • adeno-associated virus
  • anti-drug antibodies
  • functional cure
  • gene therapy
  • HIV broadly neutralizing antibodies
  • immunotherapy
  • rhesus macaques
  • SHIV infection
  • viral reservoir

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Cite this

Martinez-Navio, J. M., Fuchs, S. P., Pantry, S. N., Lauer, W. A., Duggan, N. N., Keele, B. F., ... Desrosiers, R. C. (2019). Adeno-Associated Virus Delivery of Anti-HIV Monoclonal Antibodies Can Drive Long-Term Virologic Suppression. Immunity, 50(3), 567-575.e5. https://doi.org/10.1016/j.immuni.2019.02.005

Adeno-Associated Virus Delivery of Anti-HIV Monoclonal Antibodies Can Drive Long-Term Virologic Suppression. / Martinez-Navio, José M.; Fuchs, Sebastian P.; Pantry, Shara N.; Lauer, William A.; Duggan, Natasha N.; Keele, Brandon F.; Rakasz, Eva G.; Gao, Guangping; Lifson, Jeffrey D.; Desrosiers, Ronald Charles.

In: Immunity, Vol. 50, No. 3, 19.03.2019, p. 567-575.e5.

Research output: Contribution to journalArticle

Martinez-Navio, JM, Fuchs, SP, Pantry, SN, Lauer, WA, Duggan, NN, Keele, BF, Rakasz, EG, Gao, G, Lifson, JD & Desrosiers, RC 2019, 'Adeno-Associated Virus Delivery of Anti-HIV Monoclonal Antibodies Can Drive Long-Term Virologic Suppression', Immunity, vol. 50, no. 3, pp. 567-575.e5. https://doi.org/10.1016/j.immuni.2019.02.005
Martinez-Navio JM, Fuchs SP, Pantry SN, Lauer WA, Duggan NN, Keele BF et al. Adeno-Associated Virus Delivery of Anti-HIV Monoclonal Antibodies Can Drive Long-Term Virologic Suppression. Immunity. 2019 Mar 19;50(3):567-575.e5. https://doi.org/10.1016/j.immuni.2019.02.005
Martinez-Navio, José M. ; Fuchs, Sebastian P. ; Pantry, Shara N. ; Lauer, William A. ; Duggan, Natasha N. ; Keele, Brandon F. ; Rakasz, Eva G. ; Gao, Guangping ; Lifson, Jeffrey D. ; Desrosiers, Ronald Charles. / Adeno-Associated Virus Delivery of Anti-HIV Monoclonal Antibodies Can Drive Long-Term Virologic Suppression. In: Immunity. 2019 ; Vol. 50, No. 3. pp. 567-575.e5.
@article{04bf062d564a4c04a26528aa64921f8b,
title = "Adeno-Associated Virus Delivery of Anti-HIV Monoclonal Antibodies Can Drive Long-Term Virologic Suppression",
abstract = "Although anti-retroviral drug therapy can suppress HIV viral replication, it is not a cure. Martinez-Navio et al. report the functional cure of the “Miami monkey,” in which long-term SHIV suppression was achieved after a single administration of adeno-associated viruses (AAVs) encoding broadly neutralizing antibodies. They also report that host-generated anti-antibodies can hamper the applicability of this approach.",
keywords = "AAV vector, adeno-associated virus, anti-drug antibodies, functional cure, gene therapy, HIV broadly neutralizing antibodies, immunotherapy, rhesus macaques, SHIV infection, viral reservoir",
author = "Martinez-Navio, {Jos{\'e} M.} and Fuchs, {Sebastian P.} and Pantry, {Shara N.} and Lauer, {William A.} and Duggan, {Natasha N.} and Keele, {Brandon F.} and Rakasz, {Eva G.} and Guangping Gao and Lifson, {Jeffrey D.} and Desrosiers, {Ronald Charles}",
year = "2019",
month = "3",
day = "19",
doi = "10.1016/j.immuni.2019.02.005",
language = "English (US)",
volume = "50",
pages = "567--575.e5",
journal = "Immunity",
issn = "1074-7613",
publisher = "Cell Press",
number = "3",

}

TY - JOUR

T1 - Adeno-Associated Virus Delivery of Anti-HIV Monoclonal Antibodies Can Drive Long-Term Virologic Suppression

AU - Martinez-Navio, José M.

AU - Fuchs, Sebastian P.

AU - Pantry, Shara N.

AU - Lauer, William A.

AU - Duggan, Natasha N.

AU - Keele, Brandon F.

AU - Rakasz, Eva G.

AU - Gao, Guangping

AU - Lifson, Jeffrey D.

AU - Desrosiers, Ronald Charles

PY - 2019/3/19

Y1 - 2019/3/19

N2 - Although anti-retroviral drug therapy can suppress HIV viral replication, it is not a cure. Martinez-Navio et al. report the functional cure of the “Miami monkey,” in which long-term SHIV suppression was achieved after a single administration of adeno-associated viruses (AAVs) encoding broadly neutralizing antibodies. They also report that host-generated anti-antibodies can hamper the applicability of this approach.

AB - Although anti-retroviral drug therapy can suppress HIV viral replication, it is not a cure. Martinez-Navio et al. report the functional cure of the “Miami monkey,” in which long-term SHIV suppression was achieved after a single administration of adeno-associated viruses (AAVs) encoding broadly neutralizing antibodies. They also report that host-generated anti-antibodies can hamper the applicability of this approach.

KW - AAV vector

KW - adeno-associated virus

KW - anti-drug antibodies

KW - functional cure

KW - gene therapy

KW - HIV broadly neutralizing antibodies

KW - immunotherapy

KW - rhesus macaques

KW - SHIV infection

KW - viral reservoir

UR - http://www.scopus.com/inward/record.url?scp=85062153631&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062153631&partnerID=8YFLogxK

U2 - 10.1016/j.immuni.2019.02.005

DO - 10.1016/j.immuni.2019.02.005

M3 - Article

VL - 50

SP - 567-575.e5

JO - Immunity

JF - Immunity

SN - 1074-7613

IS - 3

ER -